^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S

Published date:
05/24/2021
Excerpt:
A total of 23 patients provided valid clinical outcome data, of whom eight were treated with afatinib after the emergence of G724S, whereas 15 received non-afatinib treatment (alternative EGFR TKI, chemotherapy, or best supportive care). The disease control rate in afatinib-treated patients (n = 8) reached 100% with a median progression-free survival of 4.5 months, significantly longer than that of non-afatinib-treated (n = 15, 1.7 mo, hazard ratio [HR] = 0.32, p = 0.037)...
DOI:
10.1016/j.jtocrr.2021.100193